“The generation change in the company’s management reflects sustainable corporate development, as well as the Group’s ability to change,” said Dr. Klaus-Jürgen Schmieder, chairman of the Supervisory Board of ALTANA AG. “Under the leadership of Dr. Wolfgruber, ALTANA’s chemical business has developed extraordinarily successfully in the last 13 years while undergoing constant changes. We would like to express our sincere gratitude and great appreciation for him already today. As a longtime member of the Management Board, Martin Babilas has played a key role in the development of ALTANA’s strategy. We are convinced that he will continue to lead the company on this successful path.”
The Supervisory Board has appointed Stefan Genten as ALTANA’s new CFO as of Aug. 1, 2015. Genten worked in various management capacities for the Grünenthal pharmaceutical group for 13 years, since 2005 as a member of the Corporate Executive Board and as the CFO. He was also in charge of operative functions, for example for the Latin American business, and as Group COO for the last five years.
“We are pleased to have attracted Stefan Genten, a proven leadership personality, to ALTANA,” said Dr. Schmieder. “He will provide us with new impetus and we will benefit from his many years of international experience.”
On Jan. 1, 2016, Martin Babilas will take over responsibility for Corporate Development/M&A, Human Resources, Corporate Communications and Internal Audit from Dr. Wolfgruber. On that same date, Dr. Christoph Schlünken will assume responsibility for Innovation Management. Dr. Schlünken became a third member of ALTANA’s Management Board last November.